Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques.
The role of LRP in clinical drug resistance in acute myeloid leukemia (AML) is controversial. We therefore compared multiple assays, including RT-PCR, immunocytochemistry (ICC) and flow cytometry (FC), in 10 cell lines and in 47 fresh and thawed AML cells in order to validate and to quantitate measures for LRP phenotype detection. We also compared different ways of expressing the results. Lastly, in cell lines, we analyzed the 50% lethal concentration (LC50), by MTT assay, of cisplatin which could estimate the functionality of LRP. The reproducibility of LRP detection measured by RT-PCR, ICC and FC was good. In the same way, within the same technique, there was good correlation between the different methods of expressing the results of LRP level. Therefore, the discrepancies noted with the three techniques used were neither a problem of reproducibility nor a problem of results expression. On the other hand, there was only a correlation between ICC and FC, and no correlation between RT-PCR and LRP protein detection techniques. Therefore, RT-PCR is probably not the optimal technique for LRP detection. We have shown in 10 cell lines a higher correlation between FC and LC50 of cisplatin than between ICC and LC50 of cisplatin and no correlation between RT-PCR and LC50 of cisplatin. For five patients, there was a dissociation between ICC and FC. Four patients were positive by FC and negative by ICC and only one patient was negative by FC and positive by ICC. Therefore, if in vitro resistance to cisplatin represents the functionality of LRP, we recommend the use of FC rather than ICC to detect LRP expression. Besides the measurement of LRP as a diagnostic tool in the evaluation of resistance to chemotherapy in patients with AML, we urgently need to establish a functional test in order to assess LRP activity.
Legrand
O
O
Service d'Hématologie Biologique, Université Paris 6, Formation de Recherche Associée Claude Bernard sur le Traitement des Hémopathies Malignes, Paris, France.
Simonin
G
G
Zittoun
R
R
Marie
J P
JP
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology; D002945:Cisplatin / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007951:Leukemia, Myeloid / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D010641:Phenotype; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D015203:Reproducibility of Results; D014407:Tumor Cells, Cultured / Q000187:drug effects; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein
D000970:Antineoplastic Agents; D002945:Cisplatin; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein